References
1. Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al.
2023 Update on European
Atherosclerosis Society Consensus Statement on Homozygous Familial
Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart
J. 2023; 44: 2277-2291.
2. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L,
Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and
undertreated in the general population: guidance for clinicians to
prevent coronary heart disease: consensus statement of the European
Atherosclerosis Society. Eur Heart J 2013; 34: 3478–90.
3. Vrablik M, Tichý L, Freiberger T, Blaha V, Satny M, Hubacek JA.
Genetics of Familial
Hypercholesterolemia: New Insights. Front Genet. 2020; 11: 574474.
4. Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide
prevalence of familial hypercholesterolemia: meta-analyses of 11 million
subjects. J Am Coll Cardiol 2020;75: 2553–2566.
5. Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H,
et al.
Worldwide experience of homozygous familial hypercholesterolaemia:
retrospective
cohort study. Lancet 2022;399:719–728.
6. Bruckert E. Recommendations for the manage- ment of patients with
homozygous familial hypercholesterolaemia: overview of a new Euro- pean
Atherosclerosis Society Consensus Statement. Atheroscler Suppl. 2014;
15:26–32.
7. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS,
et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
guideline on the management of blood cholesterol: a report of the
American College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines. Circulation 2019; 139: e1082–143.
8. Bélanger AM, Akioyamen L, Alothman L, Genest J. Evidence for improved
survival with treatment of homozygous familial hypercholesterolemia.
Curr Opin Lipidol 2020; 31: 176–81.
9. France M, Rees A, Datta D, Thompson G, Capps N, Ferns G, et al. HEART
UK statement on the management of homozygous familial
hypercholesterolaemia in the United Kingdom. Atherosclerosis 2016;
255:128–139.
10. Brunham LR, Ruel I, Aljenedil S, Riviere JB, Baass A, Tu JV, et al.
Canadian Cardiovascular Society Position Statement on Familial
Hypercholesterolemia: update 2018. Can J Cardiol 2018; 34:1553–1563.
11. Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia
treatments: guidelines and new therapies. Atherosclerosis. 2018; 277:
483–492.
12. Moriarty PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients
with heterozygous familial hypercholesterolaemia undergoing lipoprotein
apheresis: the ODYSSEY ESCAPE trial. Eur Heart J 2016; 37: 3588–95.
13. Seidah NG. The PCSK9 revolution and the potential of PCSK9-based
therapies to reduce LDL- cholesterol. Glob Cardiol Sci Pract 2017; 2017:
e201702.
14. D’Erasmo L, Cefalu AB, Noto D, Giammanco A, Averna M, Pintus P, et
al. Efficacy of lomitapide in the treatment of familial homozygous
hypercholesterolemia: results of a real-world clinical experience in
Italy. Adv Ther 2017; 34: 1200–1210.
15. Berberich AJ, Hegele RA. Lomitapide for the treatment of
hypercholesterolemia. Expert Opin Pharmacother. 2017; 18: 1261–1268.
16. Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E,
et al. Long-term treatment with evolocumab added to conventional drug
therapy, with or without apheresis, in patients with homozygous familial
hypercholesterolaemia: an interim subset analysis of the open-label
TAUSSIG study. Lancet Diabetes Endocrinol 2017; 5: 280–290.
17. Thedrez A, Blom DJ, Ramin-Mangata S, et al. Homozygous familial
hypercholesterolemia patients with identical mutations variably express
the LDLR (low-density lipoprotein receptor): implications for the
efficacy of evolocumab. Arterioscler Thromb Vasc Biol. 2018; 38:
592–598.
18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC,
Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for
reporting systematic reviews. BMJ. 2021; 372: n71.
19. Higgins J.P.T., Green S., editors. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated March
2011] The Cochrane Collaboration. 2011. [(accessed on 2 December
2024)]. Available
online: www.handbook.cochrane.org
20.
Hozo
SP,
Djulbegovic
B,
Hozo
I. Estimating the mean and variance from the median, range, and the
size of a sample.
BMC
Med Res Methodol. 2005; 5:13.
21. Higgins JPT, Thompson SG. Quantifying heterogeneity in a
meta-analysis. Stat Med. 2002;21(11):1539-58.
22. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect
of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG
145, in homozygous familial hypercholesterolemia. Circulation
2013;128:2113–2120.
23. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman
SM, Stein EA; TESLA Investigators.
Inhibition of PCSK9
with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part
B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;
385: 341-50.
24. Blom DJ, Harada-Shiba M, Rubba P, Gaudet D, Kastelein JJP, Charng
MJ, et al. Efficacy and
Safety of Alirocumab in Adults With Homozygous
Familial Hypercholesterolemia: The ODYSSEY HoFH Trial. J Am Coll
Cardiol. 2020; 76: 131-142.
25. Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, López
JAG, Bray S, Kurtz CE, Hamer AW, Raal FJ.
Long-Term Evolocumab in
Patients With Familial Hypercholesterolemia. J Am Coll Cardiol. 2020
Feb 18;75(6):565-574.
26. Bruckert E, Caprio S, Wiegman A, Charng MJ, Zárate-Morales CA,
Baccara-Dinet MT, Manvelian G, Ourliac A, Scemama M, Daniels SR.
Efficacy and Safety of
Alirocumab in Children and Adolescents With Homozygous Familial
Hypercholesterolemia: Phase 3, Multinational Open-Label Study.
Arterioscler Thromb Vasc Biol. 2022;42:1447-1457.
27. Bansal S, Ruzza A, Sawhney J, Kulkarni G, Iyengar S, Mehta V, Hamer
A, Wu Y, Raal FJ.
Evolocumab in patients
with homozygous familial hypercholesterolemia in India. J Clin Lipidol.
2021;15: 814-821.
28. Banerjee P, Chan KC, Tarabocchia M, Benito-Vicente A, Alves AC,
Uribe KB, et al.
Functional Analysis of
LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes
to Assess the Effect of Evinacumab in Homozygous Familial
Hypercholesterolemia Patients With a Spectrum of LDLR Activity.
Arterioscler Thromb Vasc Biol. 2019; 39: 2248-2260.
29. Raal FJ, Rosenson RS, Reeskamp LF, et al. The long-term efficacy and
safety of evinacumab in patients with homozygous familial
hypercholesterolemia. JACC: Adv. 2023;2(9):100648.
30. Gaudet D, Greber-Platzer S, Reeskamp LF, Iannuzzo G, Rosenson RS,
Saheb S, Stefanutti C, Stroes E, Wiegman A, Turner T, Ali S, Banerjee P,
Drewery T, McGinniss J, Waldron A, George RT, Zhao XQ, Pordy R, Zhao J,
Bruckert E, Raal FJ.
Evinacumab in
homozygous familial hypercholesterolaemia: long-term safety and
efficacy. Eur Heart J. 2024; 45: 2422-2434.
31. Béliard S, Saheb S, Litzler-Renault S, Vimont A, Valero R, Bruckert
É, Farnier M, et al.
Evinacumab and
Cardiovascular Outcome in Patients With Homozygous Familial
Hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2024
Jun;44(6):1447-1454.
32. Stefanutti C, Chan DC, Dip GZ, Watts GF.
Real-world experience
of long-term efficacy and safety of evinacumab in patients with
homozygous familial hypercholesterolemia treated and not treating with
lipoprotein apheresis. J Clin Lipidol. 2024: S1933-2874 (24) 00189-2.
33. Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng
MJ, Srinivasan S, et al. Evinacumab for Pediatric Patients With
Homozygous Familial Hypercholesterolemia. Circulation. 2024; 149:
343-353.
34. Cholesterol Treatment Trialists (CTT) Collaboration; Baigent C,
Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety
of more intensive lowering of LDL cholesterol: a meta-analysis of data
from 170,000 participants in 26 randomised trials. Lancet 2010; 376:
1670–1681.
35. Gu J, Gupta RN, Cheng HK, Xu Y, Raal FJ.
Current treatments for
the management of homozygous familial hypercholesterolaemia: a
systematic review and commentary. Eur J Prev Cardiol. 2024; 31:
1833-1849.
36. France M, Rees A, Datta D, Thompson G, Capps N, Ferns G, et al.
HEART UK statement on the management of homozygous familial
hypercholesterolaemia in the United Kingdom. Atherosclerosis 2016;
255:128–139.
37. Stefanutti C, Blom DJ, Averna MR, Meagher EA, Theron HD, Marais AD,
et al. The lipid-lowering effects of lomitapide are unaffected by
adjunctive apheresis in patients with homozygous familial
hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm,
open-label trial. Atherosclerosis 2015; 240: 408–414.
38. Rossi M, Fabris E, Barbisan D, Massa L, Sinagra G. Lipid-lowering
drug therapy: critical approach for Implementation in clinical practice.
Am J Cardiovasc Drugs. 2022; 22: 141–155.
39. Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in pediatric
heterozygous familial hypercholesterolemia. N Engl J Med. 2020;
383:1317–1327.
40. Alonso R, Diaz-Diaz JL, ArrietaF, et al. Clinical and molecular
characteristics of homozygous familial hypercholesterolemia patients:
insights from SAFEHEART registry. J Clin Lipidol. 2016; 10: 953–961.